Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care …
Sponsor: NRG Oncology
NCT ID: NCT06958328
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Cooper Hospital University Medical Center — Camden, New Jersey
- Jefferson Cherry Hill Hospital — Cherry Hill, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Sponsor: Incyte Corporation
NCT ID: NCT07522073
Sites in New Jersey: - Investigative Site US077 — Hackensack, New Jersey
- Investigative Site US017 — Morristown, New Jersey
Phase 3 Recruiting Academic/Other
This study is a non-randomized, open-label, multi-cohort, multi-site, pilot feasibility therapeutic trial. The study will enroll 20 patients across 4 cohorts (CRC, gastric, PDAC, and HCC/intra-hepatic-/extra-hepatic-, gall bladder adenocar…
Sponsor: Georgetown University
NCT ID: NCT05482516
Sites in New Jersey: - John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
Phase 2 Recruiting NIH
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04858334
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Cooper Hospital University Medical Center — Camden, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
- Holy Name Hospital — Teaneck, New Jersey
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in partici…
Sponsor: Genentech, Inc.
NCT ID: NCT05968326
Sites in New Jersey: - Memorial Sloan Kettering Cancer Center Basking Ridge — Basking Ridge, New Jersey
- Memorial Sloan Kettering Cancer Center — Middletown, New Jersey
- Memorial Sloan Kettering Cancer Center at Bergen — Montvale, New Jersey
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…
Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in New Jersey: - Englewood Hospital and Medical Center (site 202) — Englewood, New Jersey
- Summit Medical Group (site 205) — Florham Park, New Jersey
- Atlantic Health System, Morristown Medical Center (site 124) — Morristown, New Jersey
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in New Jersey: - John Theurer Cancer Center — Hackensack, New Jersey
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with metastatic …
Sponsor: Engeneic Pty Limited
NCT ID: NCT07049055
Sites in New Jersey: - Atlantic Health — Summit, New Jersey
Phase 2 Recruiting Academic/Other
The goal of this clinical trial is to test the safety and tolerability of anti-CD38 monoclonal antibody (mAb), daratumumab, in combination with KRAS vaccine (Targovax TG-01/Stimulon QS-21) when given with anti-PD-1 (programmed cell death p…
Sponsor: Georgetown University
NCT ID: NCT06015724
Sites in New Jersey: - John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
Phase 1 Recruiting Industry
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
Sponsor: Clasp Therapeutics, Inc.
NCT ID: NCT06778863
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
Phase 1 Recruiting Industry
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.
Sponsor: AstraZeneca
NCT ID: NCT05877599
Sites in New Jersey: - Research Site — New Brunswick, New Jersey
Phase 1 Recruiting Industry
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects with Advanced or Metastatic Solid Tumors.
Sponsor: SystImmune Inc.
NCT ID: NCT07021066
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
Phase 1 Recruiting Industry
Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors. ASP2138 is thought to bind to CLDN18.2 and a…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT05365581
Sites in New Jersey: - Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 1 Recruiting Industry
This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.
Sponsor: I-Mab Biopharma US Limited
NCT ID: NCT04900818
Sites in New Jersey: - Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 1 Recruiting Industry
Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the…
Sponsor: Astellas Pharma Inc
NCT ID: NCT07094204
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
Phase 1 Recruiting Industry
This is a Phase 1a/1b open-label, dose escalation study to evaluate the safety and efficacy of CT-95 (study drug), a humanized T cell engaging bispecific antibody targeting Mesothelin, in subjects with advanced solid tumors associated with…
Sponsor: Context Therapeutics Inc.
NCT ID: NCT06756035
Sites in New Jersey: - Context Investigational Site — Hackensack, New Jersey
Phase 1 Recruiting Industry
This study is open to adults with advanced cancer of the colon, rectum, stomach, or pancreas, that is the cancer cannot be removed by surgery or has spread. People can take part in this study if their previous treatment was not successful,…
Sponsor: Boehringer Ingelheim
NCT ID: NCT06882746
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
Phase 1 Recruiting Industry
This is a Phase 1a, open label, single dose, extended study of safety and biokinetics of RAD301 in healthy human volunteers and individuals with PDAC or Other Solid Tumors
Sponsor: Radiopharm Theranostics, Ltd
NCT ID: NCT05799274
Sites in New Jersey: - United Theranostics — Princeton, New Jersey
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in New Jersey: - Englewood Hospital and Medical Center — Englewood, New Jersey
- CentraState Medical Center — Freehold, New Jersey
- Hackettstown Medical Center — Hackettstown, New Jersey
- Morristown Medical Center — Morristown, New Jersey
- Inspira Medical Center Mullica Hill — Mullica Hill, New Jersey
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in New Jersey: - Massive Bio SYNERGY-AI site — New Brunswick, New Jersey
Recruiting Academic/Other
The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individ…
Sponsor: Arbor Research Collaborative for Health
NCT ID: NCT04970056
Sites in New Jersey: - Hackensack Meridian Health — Hackensack, New Jersey
Recruiting Academic/Other
The RSSearch® Registry is an international multi-year database designed to track SRS/SBRT (Stereotactic Radiosurgery/Stereotactic Body Radiation Therapy) utilization, treatment practices and outcomes to help determine, over time, the most …
Sponsor: The Radiosurgery Society
NCT ID: NCT01885299
Sites in New Jersey: - AtlantiCare Regional Medical Center and AtlantiCare Cancer Care Institute — Egg Harbor, New Jersey
- Riverview Medical Center — Red Bank, New Jersey
- NJ Cyberknife at Community Medical Center — Toms River, New Jersey
Recruiting Academic/Other
The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients …
Sponsor: University of Louisville
NCT ID: NCT02674100
Sites in New Jersey: - Atlantic Health — Millburn, New Jersey
Recruiting Academic/Other
The purpose of this study is to develop a minimally invasive test to diagnose pancreatic cancer at early stages of disease and monitor response to treatment.
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT03334708
Sites in New Jersey: - Memorial Sloan Kettering Monmouth (All protocol activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All protocol activities) — Montvale, New Jersey
Recruiting Academic/Other
This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.
Sponsor: City of Hope Medical Center
NCT ID: NCT06388967
Sites in New Jersey: - Atlantic Health System — Morristown, New Jersey